Our work provides evidence that silence or down-regulation of RAI2 in colorectal cancer may contribute to aberrant activation of Wnt signaling pathway, and consequently promote chemoresistance of CRC cells to chemotherapy drugs such as oxaliplatin and fluorouracil. This evidence concerns the gene RAI2 and colorectal cancer.